Edition:
United States

Abeona Therapeutics Inc (ABEO.OQ)

ABEO.OQ on NASDAQ Stock Exchange Capital Market

16.10USD
2:26pm EST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$16.10
Open
$16.20
Day's High
$16.40
Day's Low
$15.90
Volume
101,607
Avg. Vol
240,008
52-wk High
$22.70
52-wk Low
$4.05

Chart for

About

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin... (more)

Overall

Beta: 2.22
Market Cap(Mil.): $753.08
Shares Outstanding(Mil.): 46.78
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 196.13 16.04
EPS (TTM): -- -- --
ROI: -- -11.69 35.70
ROE: -- -36.44 15.40

BRIEF-Abeona Q3 loss per share $0.13

* Abeona reports third quarter 2017 financial results and recent business highlights

Nov 15 2017

BRIEF-Abeona Therapeutics prices offering of five million shares at $16 per share

* Pricing underwritten public offering of five million shares of common stock at a public offering price of $16.00 per share​ Source text for Eikon: Further company coverage:

Oct 16 2017

BRIEF-Abeona Therapeutics announces public offering of common stock

* Abeona Therapeutics announces public offering of common stock Source text for Eikon: Further company coverage:

Oct 16 2017

BRIEF-Abeona Therapeutics to receive $13.85 mln of grants for development of Sanfilippo gene therapy programs​

* Abeona Therapeutics Inc - ‍nine global foundations collaborate to grant $13.85 million for continued advancement of lead Sanfilippo gene therapy programs​ Source text for Eikon: Further company coverage:

Oct 16 2017

BRIEF-Abeona Therapeutics enrolls first two patients in phase 1/2 clinical trial in MPS IIIA

* Abeona Therapeutics enrolls first two patients in pivotal expansion of phase 1/2 clinical trial in MPS IIIA

Oct 11 2017

BRIEF-ABEONA ANNOUNCES TOP-LINE ONE YEAR DATA FROM ABO-102 MPS IIIA TRIAL

* ABEONA ANNOUNCES TOP-LINE ONE YEAR DATA FROM ABO-102 MPS IIIA TRIAL AT ARM’S CELL & GENE MEETING ON THE MESA

Oct 06 2017

BRIEF-Viking Global Investors reports 5.6 percent passive stake in Abeona Therapeutics

* Viking Global Investors Lp reports 5.6 percent passive stake in Abeona Therapeutics Inc ‍​as of Sept 22 - SEC filing Source: (http://bit.ly/2yEgWSq) Further company coverage:

Oct 02 2017

BRIEF-Abeona Therapeutics and Brammer Bio announce collaboration for commercial translation of ABO-102

* Abeona Therapeutics and Brammer Bio announce collaboration for commercial translation of ABO-102

Sep 28 2017

BRIEF-Adage Capital Partners reports 5.4 pct passive stake in Abeona Therapeutics

* Adage Capital Partners LP reports 5.40 pct passive stake in as of Sept 6 - SEC filing Source text: [http://bit.ly/2yddoHo] Further company coverage:

Sep 15 2017

BRIEF-Abeona Therapeutics receives FDA breakthrough therapy designation for EB-101

* Abeona Therapeutics receives FDA breakthrough therapy designation for EB-101 autologous cell therapy in Epidermolysis Bullosa

Aug 29 2017

Earnings vs. Estimates